GLEAM: Noninvasive Glucose Measurement Using Impedance Tomography - Trial NCT06223204
Access comprehensive clinical trial information for NCT06223204 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Diabetes Mellitus. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insel Gruppe AG, University Hospital Bern
Timeline & Enrollment
N/A
Feb 01, 2024
Jan 31, 2025
Primary Outcome
Change of the electrical impedance tomography (EIT) signal of the thoracic region across the glycemic trajectory.
Summary
The GLEAM study aims at assessing the potential of electrical impedance tomography (EIT) for
 noninvasive glucose measurement.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06223204
Non-Device Trial